Current cancer immunotherapy has limited response rates in a large variety of solid tumors
partly due to the low immunogenicity of the tumor cells and the immunosuppressive tumor …

Tumor immunotherapy is only effective in a fraction of patients due to a low response rate
and severe side effects, and these challenges of immunotherapy in clinics can be addressed …

Cancer nanomedicines have shown promise in combination immunotherapy, thus far mostly
preclinically but also already in clinical trials. Combining nanomedicines with …

Immunogenic cell death (ICD) is a special pattern of tumor cell death, enabling to elicit tumor‐
specific immune response via the release of damage‐associated molecular patterns and …

Low immunogenicity and immunosuppressive tumor microenvironments are major hurdles
in the application of cancer immunotherapy. To date, several immunogenic cell death (ICD) …

Tumor immunotherapy, especially immune checkpoint blockade (ICB), has revolutionized
the cancer field. However, the limited response of tumors to immunotherapy is a major …

The immune system is involved in the initiation and progression of cancer. Research on
cancer and immunity has contributed to the development of several clinically successful …

Immunogenic cell death (ICD, also known as immunogenic apoptosis) of malignant cells is
confirmed to activate the host immune system to prevent, control, and eliminate tumors …

Cancer immunotherapy has veered the paradigm of cancer treatment. Despite recent
advances in immunotherapy for improved antitumor efficacy, the complicated tumor …

Immunotherapy is considered to be one of the most promising methods to overcome cancer.
Immunogenic cell death (ICD), as a special form of cell death that can trigger an antitumor …